S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
Spotify sounding better to analysts as company tunes into profits
Is Gold Really Boring? (Ad)
3 Reasons the Capital One-Discover merger is a big deal
How major US stock indexes fared Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Range-bound Home Depot stock still is, lower prices ahead
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
Spotify sounding better to analysts as company tunes into profits
Is Gold Really Boring? (Ad)
3 Reasons the Capital One-Discover merger is a big deal
How major US stock indexes fared Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Range-bound Home Depot stock still is, lower prices ahead
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
Spotify sounding better to analysts as company tunes into profits
Is Gold Really Boring? (Ad)
3 Reasons the Capital One-Discover merger is a big deal
How major US stock indexes fared Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Range-bound Home Depot stock still is, lower prices ahead
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
Spotify sounding better to analysts as company tunes into profits
Is Gold Really Boring? (Ad)
3 Reasons the Capital One-Discover merger is a big deal
How major US stock indexes fared Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Range-bound Home Depot stock still is, lower prices ahead

Exact Sciences (EXAS) Competitors

$63.29
+0.55 (+0.88%)
(As of 02/21/2024 ET)

EXAS vs. DGX, NTRA, EXEL, LH, RGEN, UHS, TECH, LEGN, TFX, and MEDP

Should you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Quest Diagnostics (DGX), Natera (NTRA), Exelixis (EXEL), Laboratory Co. of America (LH), Repligen (RGEN), Universal Health Services (UHS), Bio-Techne (TECH), Legend Biotech (LEGN), Teleflex (TFX), and Medpace (MEDP). These companies are all part of the "medical" sector.

Exact Sciences vs.

Exact Sciences (NASDAQ:EXAS) and Quest Diagnostics (NYSE:DGX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

Exact Sciences has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Quest Diagnostics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

In the previous week, Exact Sciences had 12 more articles in the media than Quest Diagnostics. MarketBeat recorded 26 mentions for Exact Sciences and 14 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 0.93 beat Exact Sciences' score of -0.01 indicating that Quest Diagnostics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Exact Sciences
6 Very Positive mention(s)
1 Positive mention(s)
10 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Quest Diagnostics
7 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

89.1% of Exact Sciences shares are held by institutional investors. Comparatively, 87.8% of Quest Diagnostics shares are held by institutional investors. 1.3% of Exact Sciences shares are held by company insiders. Comparatively, 0.7% of Quest Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Quest Diagnostics has a net margin of 9.23% compared to Exact Sciences' net margin of -11.73%. Quest Diagnostics' return on equity of 15.79% beat Exact Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Exact Sciences-11.73% -9.19% -4.46%
Quest Diagnostics 9.23%15.79%7.40%

Exact Sciences received 426 more outperform votes than Quest Diagnostics when rated by MarketBeat users. Likewise, 72.39% of users gave Exact Sciences an outperform vote while only 49.76% of users gave Quest Diagnostics an outperform vote.

CompanyUnderperformOutperform
Exact SciencesOutperform Votes
944
72.39%
Underperform Votes
360
27.61%
Quest DiagnosticsOutperform Votes
518
49.76%
Underperform Votes
523
50.24%

Exact Sciences currently has a consensus target price of $99.93, indicating a potential upside of 57.90%. Quest Diagnostics has a consensus target price of $146.91, indicating a potential upside of 15.92%. Given Exact Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Exact Sciences is more favorable than Quest Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exact Sciences
0 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.85
Quest Diagnostics
0 Sell rating(s)
7 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.30

Quest Diagnostics has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exact Sciences$2.41B4.76-$623.51M-$1.59-39.81
Quest Diagnostics$9.25B1.54$854M$7.4916.92

Summary

Exact Sciences beats Quest Diagnostics on 10 of the 18 factors compared between the two stocks.


Get Exact Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EXAS vs. The Competition

MetricExact SciencesMedical laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$11.45B$1.84B$4.94B$7.33B
Dividend YieldN/A1.88%2.92%3.85%
P/E Ratio-39.806.17103.1316.75
Price / Sales5.4954.383,003.4857.71
Price / CashN/A8.0990.2354.03
Price / Book3.693.304.284.56
Net Income-$623.51M-$139.28M$111.89M$207.12M
7 Day Performance1.93%-3.39%1.66%0.64%
1 Month Performance-3.89%7.11%7.19%4.47%
1 Year Performance3.31%-15.87%7.06%3.73%

Exact Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DGX
Quest Diagnostics
4.9499 of 5 stars
$123.80
-0.2%
$146.91
+18.7%
-11.7%$13.92B$9.25B16.5349,000
NTRA
Natera
0.967 of 5 stars
$70.41
+0.6%
$72.85
+3.5%
+47.3%$8.46B$820.22M-15.583,018Upcoming Earnings
Analyst Upgrade
EXEL
Exelixis
4.9992 of 5 stars
$20.63
+0.7%
$25.94
+25.7%
+18.7%$6.25B$1.83B32.231,310
LH
Laboratory Co. of America
4.8814 of 5 stars
$215.65
-0.5%
$241.86
+12.2%
-11.9%$18.31B$12.16B46.1880,000Earnings Report
Analyst Revision
RGEN
Repligen
3.2928 of 5 stars
$199.73
-4.2%
$192.50
-3.6%
+9.0%$11.15B$801.54M98.392,025News Coverage
Gap Down
UHS
Universal Health Services
4.4763 of 5 stars
$162.43
+0.2%
$159.07
-2.1%
+9.9%$11.09B$13.40B17.0493,800Upcoming Earnings
TECH
Bio-Techne
4.9801 of 5 stars
$70.33
-1.8%
$84.11
+19.6%
-2.6%$11.06B$1.14B50.963,050Positive News
Gap Down
LEGN
Legend Biotech
1.5951 of 5 stars
$60.10
+3.4%
$82.41
+37.1%
+24.9%$10.93B$117M0.001,390
TFX
Teleflex
4.0913 of 5 stars
$250.95
0.0%
$269.30
+7.3%
+4.0%$11.79B$2.79B29.4215,500News Coverage
MEDP
Medpace
4.5164 of 5 stars
$384.14
-1.9%
$377.67
-1.7%
+94.2%$11.82B$1.89B43.265,900Insider Selling

Related Companies and Tools

This page (NASDAQ:EXAS) was last updated on 2/22/2024 by MarketBeat.com Staff